Trump’s Health Stock Bets: UnitedHealth Up 19% Amid 377 Trades in 2026

For healthcare executives and investors, the trading patterns from President Trump’s recent financial disclosure offer a real-world barometer of sector sentiment. With 377 health trades in under three months and UnitedHealth shaking off a DOJ investigation to post a 19% gain, the cluster raises questions about the recovery of managed care and the regulatory landscape.

President Donald Trump’s latest financial disclosure, made public on June 21, 2026, unveils an extraordinary burst of trading activity, with 377 health care stock transactions executed in the first three months of the year. The trades, valued between $13 million and $37 million based on federal disclosure brackets, are part of a broader pattern: Trump’s accounts logged 3,642 total transactions from January 6 through March 30, as analyzed by CBS News. The sheer volume has drawn attention not only for its potential conflicts of interest but also for what it might signal about the health care sector’s near-term direction.

“

For instance, a single UnitedHealth sale reported in the “$1,000,001 – $5,000,000” bracket accounts for the stock’s wide range, layered over dozens of smaller buys and sells.

The health care trades span a range of names, but the clear standout is UnitedHealth Group. The insurance giant’s stock has surged more than 19% year-to-date in 2026, staging a remarkable comeback after a punishing 2025. That year, UnitedHealth suffered a leadership crisis when CEO Andrew Witty stepped down in May, and the board reinstated former chief Stephen Hemsley. Simultaneously, the Department of Justice opened an investigation into Medicare billing practices, sending shares sharply lower. The 2026 rebound suggests investors are betting the company has moved past those headwinds, with growth in Medicare Advantage and commercial enrollment providing fundamental support. Humana is another top performer amid Trump’s basket, although its gains are less pronounced.

However, the rest of the heavily traded health stocks have largely lagged, with most names showing declines in 2026. This dispersion underscores that simply mirroring the president’s trades is no guarantee of profits. The Trump Organization insists that outside advisers manage the accounts and that Trump and his family play no role in investment decisions. This separation raises questions about whether the trades are truly “presidential” signals at all. For retail investors, it means the activity could be a noisy blend of algorithmic trading, tax-loss harvesting, or sector rotation rather than a coherent bet based on insider policy knowledge.

The disclosure, mandated by federal ethics laws, requires officials to report transactions in predefined dollar ranges, which can obscure precise valuations. For instance, a single UnitedHealth sale reported in the “$1,000,001 – $5,000,000” bracket accounts for the stock’s wide range, layered over dozens of smaller buys and sells. Such opacity frustrates attempts to decode a clear trading strategy. Still, the activity pattern suggests that the accounts were not simply taking passive positions; the 377 health trades represent an unusually high level of churn for a portfolio of this size.